

**S5 Table.** Multivariate analysis of OS in RECIST-PD patients

	In RECIST-PD patients		
	OS		
	HR	95% CI	p-value
Age (yr)			
< 65	1		
≥ 65	1.02	0.57-1.81	0.94
Sex			
Female	1		
Male	1.36	0.67-2.73	0.37
Location			
Colon/S-colon	1		
Rectum	1.14	0.59-2.186	0.70
Histological type			
Well/Moderate differentiation	1		
Poor differentiation/Mucinous/ Signet ring cell	2.54	1.04-6.17	0.04
Metastatic presentation			
Metachronous	1		
Synchronous	1.16	0.62-2.16	0.64
Number of metastatic organs			
Only one (1)	1		
More than one (≥ 2)	2.04	1.10-3.73	0.02
First line chemotherapy			
FOLFOX/FOLFIRI	1		
FOLFOX/FOLFIRI+target agent	0.61	0.25-1.48	0.28
CEA-Response			
CEA-CR	0.37	0.14-0.975	0.04
CEA-PR	1.04	0.36-2.96	0.95
CEA-SD	1.00	0.49-2.049	0.99
CEA-PD	1		

CEA, carcinoembryonic antigen; RECIST, Response Evaluation Criteria in Solid Tumors; PD, progressive disease; OS, overall survival; HR, hazards ratio; CI, confidence interval; FOLFOX, oxaliplatin plus fluorouracil and leucovorin; FOLFIRI, cetuximab plus irinotecan, fluorouracil, and leucovorin; CR, complete response; PR, partial response; SD, stable disease.